R&D knowledge management is the practice of capturing, organizing, and making retrievable the knowledge a research organization generates, so it accumulates instead of dissipating. Every program produces reports, experiments, analyses, and decisions, and most of that knowledge is scattered across documents and people. When it cannot be found, it is repeated, and when a person leaves, it is lost.

The cost is concrete. Teams re-run experiments that were already done, revisit questions that were already answered, and lose the reasoning behind past decisions when the people who made them move on. This is the tribal knowledge problem, and it compounds negatively as an organization grows. This article explains how AI-powered knowledge management changes that, and how internal knowledge becomes most valuable when connected to the external research record.

What R&D knowledge management involves

R&D knowledge management spans two bodies of knowledge. The first is internal: research reports, experimental results, technical decisions, and the reasoning behind them. The second is external: the patents, scientific literature, and competitive activity that place internal work in context. The goal is to make both retrievable in a way that reflects how researchers actually think about a problem, rather than by filename or folder.

The defining requirement is retrieval by meaning. A researcher rarely knows the exact document title or keyword; they know the problem. Knowledge management is only useful if a question about a compound, a method, or a decision returns the relevant internal work regardless of how it was originally labeled.

Why traditional knowledge management fails in R&D

Traditional knowledge management relies on folders, tags, and keyword search over document stores. It fails in R&D for the same reasons keyword search fails elsewhere: the same concept is described in different words across teams and years, so a query built on expected terms misses relevant work. Documents are siloed by team and system, and the connection between a past experiment and a current question is invisible.

It also fails at the human boundary. When knowledge lives in individuals rather than a retrievable system, staff turnover erases it. A traditional document repository preserves files but not the ability to find the right one at the right moment, which is the part that actually matters.

How AI changes R&D knowledge management

AI-powered knowledge management applies semantic search to internal knowledge, so a question returns relevant reports, results, and decisions by meaning rather than exact keywords. An R&D ontology organizes that knowledge by technical concept and connects related work, so a current problem surfaces the past work that bears on it even when the vocabulary differs.

The larger shift is connecting internal knowledge to the external record. When internal research is organized in the same conceptual structure as the external patent and scientific literature, a single question can reach both: what the team already knows, and what the wider field has published or patented. That connection is what turns a static archive into an intelligence layer.

Why connected knowledge compounds

Knowledge compounds when each new piece of work is retrievable in the context of everything before it and everything outside it. An experiment recorded today becomes findable the next time a related question arises; a past decision retains its reasoning; a current program is checked against both internal history and the external landscape before resources are committed. Instead of decaying as people leave and volume grows, the organization's knowledge becomes more valuable over time.

This is the difference between storing knowledge and compounding it. Storage preserves documents; compounding makes the whole body of work usable on every new question.

R&D knowledge management in practice

Cypris addresses this through its Knowledge Management product, which makes an organization's research knowledge retrievable and connects it to the external record. Internal work is organized through the same proprietary R&D ontology that structures a corpus of more than 500 million patents and scientific papers, so a single semantic query reaches both internal knowledge and the external patent and scientific literature.

Cypris Q, the platform's agentic layer, lets teams interrogate that combined knowledge in natural language and returns cited output, so a question about a compound or a program draws on internal history and external context at once. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

FAQ

What is R&D knowledge management?

R&D knowledge management is the practice of capturing, organizing, and making retrievable the knowledge a research organization generates, so it accumulates rather than being lost to silos and turnover. It covers internal reports, experiments, and decisions, and connects them to the external patent and scientific record.

Why does R&D lose institutional knowledge?

R&D loses institutional knowledge because much of it lives in individuals and scattered documents rather than a retrievable system, so it disappears when people leave or when work cannot be found. This tribal knowledge problem leads teams to repeat experiments and lose the reasoning behind past decisions.

Why does traditional knowledge management fail in R&D?

Traditional knowledge management fails in R&D because folder-and-keyword systems miss work described in different terms across teams and years, and they silo documents by system. They preserve files but not the ability to find the right one at the right moment, which is the part that matters.

How does AI improve R&D knowledge management?

AI improves R&D knowledge management by applying semantic search, so a question returns relevant internal work by meaning rather than exact keywords. An R&D ontology organizes knowledge by technical concept and connects related work, and links internal knowledge to the external patent and scientific record.

What is tribal knowledge and why does it matter?

Tribal knowledge is the undocumented understanding held by individuals in an organization, such as why a decision was made or how a method actually works. It matters because it is lost when people leave, and capturing it in a retrievable system is a central goal of R&D knowledge management.

How does knowledge management connect internal work to external research?

Knowledge management connects internal work to external research by organizing both in the same conceptual structure, so a single question reaches internal reports and the external patent and scientific literature together. This places a team's own work in the context of what the wider field has published or patented.

What does it mean for knowledge to compound?

Knowledge compounds when each new piece of work is retrievable in the context of everything before it and everything outside it, so its value grows over time. Instead of decaying as staff turn over and volume rises, the organization's body of work becomes more usable on every new question.

Is R&D knowledge management just a document repository?

R&D knowledge management is more than a document repository, because storage alone preserves files without making the right one findable at the right moment. The value is in retrieval by meaning and in connecting internal knowledge to the external record, not in archiving.

Which teams benefit most from R&D knowledge management?

Research-intensive organizations benefit most from R&D knowledge management, particularly in pharmaceuticals, chemicals, advanced materials, and energy, where programs are long, knowledge is technical, and turnover erases hard-won understanding. These teams gain the most from preserving and connecting institutional knowledge.

What is the best platform for R&D knowledge management?

The best platform for R&D knowledge management makes internal knowledge retrievable by meaning and connects it to the external research record. Cypris does this through its Knowledge Management product, organizing internal work through the same R&D ontology that structures a corpus of more than 500 million patents and scientific papers.

‍

mRNA therapeutics have moved from pandemic response to a broad modality, and their patent landscape is distinctive because the mRNA molecule is patented separately from the lipid nanoparticle that delivers it. This article addresses the construct itself. A therapeutic mRNA is engineered in several parts, and each is a distinct region of patenting: the modified nucleosides, such as pseudouridine variants, that reduce the innate immune response, an insight foundational to making mRNA usable in humans;¹ the five-prime cap that enables translation;² the untranslated regions that tune expression;³ the poly-A tail that stabilizes the molecule and, with the cap, defines the ends that are engineered for therapeutic performance;⁴ the sequence and codon optimization that improves output; and, increasingly, the self-amplifying and trans-amplifying designs that let a smaller dose replicate inside the cell. Rational-design analyses describe the construct as exactly this layered assembly, from cap through untranslated regions and open reading frame to poly-A tail, and the choice of nucleoside modification continues to shape immunogenicity.⁵,⁶ Because these elements can be claimed independently and are often held by different owners, and because delivery adds its own separate estate, freedom-to-operate for an mRNA product is a multi-layer, multi-owner analysis rather than a single clearance.

The field's IP has been defined by landmark disputes, which have raised the stakes across every layer. Foundational modified-nucleoside discoveries originated in academic work and are licensed through a chain of sublicenses, and the leading commercial developers have litigated over who owns and who may use the core construct technologies. Several of these cases have moved through courts in the United States and through the European Patent Office: one developer's settlement arrangements to resolve pending mRNA vaccine litigation with two others were entered on August 7, 2025,⁷ while a series of European construct patents were revoked or narrowed in opposition proceedings, with a further opposed patent maintained in amended form.⁸ The practical result is that a developer can hold a strong position on its own sequence and still face freedom-to-operate exposure on the nucleoside chemistry, the untranslated regions, or the tail, plus the separate delivery layer. This shows in the record: across the Cypris corpus of more than 500 million patents and scientific papers, the mRNA vaccine and therapeutics set holds on the order of 16,694 families and grew from about 582 in 2020 to roughly 2,062 in 2024, with the most active assignees including ModernaTx, Translate Bio, CureVac, the University of Pennsylvania, MIT, and BioNTech, and the United States far ahead of China and Germany on geography; 2025 and 2026 counts are partial because of the publication lag.

The strategic picture turns on where defensible, hard-to-design-around IP sits. The foundational modified-nucleoside and core-structure estates are comparatively crowded and heavily licensed, so the open, high-value ground is increasingly in self-amplifying and trans-amplifying mRNA, in novel nucleoside modifications and sequence-engineering methods, in untranslated-region and structural designs that improve durability and expression, in enzymatic capping and manufacturing methods, and in mRNA applications beyond vaccines.⁷ Self-amplifying mRNA has now reached the market: the first self-amplifying mRNA vaccine, which encodes a replicase alongside the antigen so the molecule copies itself inside the cell, was approved in Japan in 2023 and by the European Commission in February 2025, though not, as of this writing, in the United States.⁹ Circular RNA and other next-generation constructs are a further frontier. Reading the landscape by construct layer and by owner, and tracking both the patents and the underlying RNA-biology research, is what separates a workable position from a blocked one.

What creates FTO risk in mRNA constructs

Modified-nucleoside claims. These cover the chemistries, such as pseudouridine variants, that reduce immune activation, a foundational and heavily licensed layer.¹,⁶

Cap and untranslated-region claims. These cover the five-prime cap and the untranslated regions that enable and tune translation, a distinct expression-control layer.²,³

Poly-A tail and stability claims. These cover the tail and other end-engineering technologies, a separately owned and actively litigated layer.⁴

Sequence and codon-optimization claims. These cover methods to improve protein output from a given sequence, which can carry their own IP.

Self-amplifying and next-generation-construct claims. These cover self-amplifying, trans-amplifying, and circular-RNA designs, an emerging and comparatively open layer.⁹

How AI-powered landscape and FTO analysis helps

A modular, multi-owner, litigation-shaped landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant nucleoside, cap, untranslated-region, tail, and self-amplifying claims regardless of terminology, attribution that resolves academic and commercial owners and the sublicense chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and disputes. Because RNA-biology advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as mRNA therapeutics across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by construct layer, modified nucleoside, cap, untranslated region, poly-A tail, and self-amplifying design, and normalizes academic and commercial owners and their sublicense chains to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list, and can separate the construct estate from the delivery estate. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where new modifications and constructs emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is mRNA construct IP separate from delivery IP? mRNA construct IP is separate from delivery IP because the mRNA molecule and the lipid nanoparticle that carries it are distinct inventions with distinct owners. The construct covers the nucleosides, cap, untranslated regions, tail, and sequence; the delivery covers the lipid formulation. Freedom-to-operate must clear both estates separately.

Why were modified nucleosides so important? Modified nucleosides were important because replacing a natural nucleoside with a modified form, such as a pseudouridine variant, sharply reduced the innate immune response that had previously made mRNA unsuitable as a drug. This breakthrough helped enable therapeutic mRNA. The foundational nucleoside estates are therefore central to the landscape.

What claim types create FTO risk in mRNA constructs? Five claim types create FTO risk: modified-nucleoside claims, cap and untranslated-region claims, poly-A tail and stability claims, sequence and codon-optimization claims, and self-amplifying and next-generation-construct claims. Each covers a distinct layer and can be held by a different owner. The nucleoside and stability layers have been especially contested.

Why has mRNA IP been so heavily litigated? mRNA IP has been heavily litigated because the modality became commercially enormous very quickly, foundational construct technologies are held by a small number of parties, and their scope overlaps. Disputes have run through courts and the European Patent Office, with some resolved by settlement, including arrangements entered in August 2025, and others contested in opposition proceedings. The outcomes shape licensing across the field.

Has a self-amplifying mRNA product been approved? Yes. The first self-amplifying mRNA vaccine, which encodes a replicase so the mRNA copies itself inside cells, was approved in Japan in 2023 and by the European Commission in February 2025. It had not been approved in the United States as of this writing. Self-amplifying designs aim to achieve a given effect at a lower dose.

Where is the white space in mRNA therapeutics? The white space includes self-amplifying and trans-amplifying mRNA, novel nucleoside modifications and sequence engineering, untranslated-region and structural designs, enzymatic capping and manufacturing, circular RNA, and applications beyond vaccines. The foundational construct layers are crowded and licensed. The durable, defensible value is in next-generation constructs and new applications.

What software helps analyze the mRNA therapeutics patent landscape? Software for the mRNA landscape should resolve academic and commercial owners and sublicense chains to canonical entities, separate the construct and delivery estates, cluster the nucleoside, cap, untranslated-region, tail, and self-amplifying layers, search patents and scientific literature semantically, and monitor disputes and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.

Which teams need mRNA patent landscape and FTO analysis? mRNA patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at mRNA and vaccine companies, as well as investors assessing mRNA assets. The modular, litigation-shaped landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

Endnotes

1. Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2). https://doi.org/10.1016/j.immuni.2005.06.008
2. Kore, A. R., Senthilvelan, A., & Shanmugasundaram, M. (2022). Recent advances in modified cap analogs for mRNA-based vaccines. The Chemical Record, 22(9). https://doi.org/10.1002/tcr.202200005
3. Zhang, H., et al. (2024). Optimization of the 5′ untranslated region of mRNA vaccines. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-70792-x
4. Jemielity, J., et al. (2023). Chemical modifications of mRNA ends for therapeutic applications. Accounts of Chemical Research, 56(20). https://doi.org/10.1021/acs.accounts.3c00442
5. To, K. K. W., & Cho, W. C. S. (2021). An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opinion on Drug Discovery, 16(11). https://doi.org/10.1080/17460441.2021.1935859
6. Liu, Y. (2026). The impact of nucleotide modifications on the immune responses of mRNA vaccines. https://doi.org/10.54097/bmddk068
7. CureVac N.V. (2025). CureVac announces resolution of patent litigation with Pfizer/BioNTech (Form 6-K, Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1809122/000110465925075352/tm2522930d1_ex99-1.htm
8. CureVac N.V. (2025). CureVac receives positive validity decision from the European Patent Office in litigation against BioNTech SE (Form 6-K, Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1809122/000110465925028798/tm2510706d1_ex99-1.htm
9. European Medicines Agency (2024). Kostaive (zapomeran): EPAR public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/kostaive-epar-public-assessment-report_en.pdf

‍

Antibody-drug conjugates are among the most active areas of oncology drug development, and their patent landscape is distinctive because an ADC is a modular product whose components are patented separately. An ADC joins a monoclonal antibody to a cytotoxic payload through a chemical linker, using a defined conjugation chemistry and a specified drug-to-antibody ratio. Each of these elements, the antibody, the linker, the payload, the conjugation site and chemistry, and the ratio, can be claimed independently, so freedom-to-operate risk is layered across several distinct patent families held by different owners. Freedom-to-operate determines whether making, using, or selling a product would infringe another party's active patent claims, and peer-reviewed analysis of ADC intellectual property has long stressed that the assessment must cover every layer, not the molecule as a whole.¹

The landscape has grown intensely. A peer-reviewed update to the ADC patent literature notes that, a decade after the first ADC patent-landscape review, the basic principles still apply but the field has expanded and matured substantially, with next-generation payloads, linkers, and site-specific conjugation driving new filings.² That expansion is visible in the patent record: across the Cypris corpus of more than 500 million patents and scientific papers, ADC-specific patent families more than doubled from about 2,645 in 2018 to about 5,949 in 2024, with 2025 counts partial because of the roughly eighteen-month publication lag. The growth has been propelled by potent topoisomerase-1 payloads such as the deruxtecan and govitecan classes, new linker and site-specific conjugation technologies, and the expansion of ADCs from hematologic cancers into solid tumors. Peer-reviewed patent reviews map the issued patents onto specific linker and payload technologies,³ and document filing activity concentrated among a small set of leading developers, with more than a dozen approved ADCs and a large clinical pipeline behind the trend.⁴ Within the Cypris corpus, conjugation and site-specific chemistry and the linker layer are the most heavily worked parts of the ADC set, consistent with where litigation and FTO risk concentrate.

Litigation has made the stakes concrete, and it has centered on the linker layer. In the multi-year dispute between Seagen and Daiichi Sankyo over the linker technology used in a blockbuster HER2-targeted ADC, a jury had found for Seagen and awarded damages, but on December 2, 2025 the US Court of Appeals for the Federal Circuit reversed, holding Seagen's key linker patent invalid for lack of written description and non-enablement and vacating the damages award.⁵ The court reasoned that the priority disclosure did not convey possession of the specific claimed subgenus of linkers and that a broad functional claim was not enabled.⁵ For developers, the practical lesson is twofold: the linker and conjugation layer is heavily contested and a frequent source of FTO risk, and the proprietary payload estates built around leading platforms, such as the DXd payload, create freedom-to-operate exposure for follow-on and biosimilar ADCs in markets where those estates are in force. That exposure is concentrated: across the Cypris corpus, the most active assignees in the ADC-specific set include Genentech, Seagen, Daiichi Sankyo, Regeneron, Immunomedics, and ImmunoGen, several of which anchor the payload and linker estates most likely to surface in an FTO search. Because applications publish about eighteen months after filing, the newest linker, payload, and conjugation filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

What creates FTO risk in ADCs

Antibody claims. These cover the targeting antibody and its engineering, a distinct layer that can implicate separate antibody IP.

Linker claims. These cover cleavable and non-cleavable linkers and their chemistry, the layer most heavily litigated, as the Seagen v. Daiichi Sankyo dispute demonstrates.⁵

Payload claims. These cover the cytotoxic agent, including proprietary payload estates built around specific classes, which create FTO exposure for follow-on products.

Conjugation and site-specific claims. These cover how payload and antibody are joined and where, an area of intense recent innovation and patenting.³

Drug-to-antibody ratio and formulation claims. These cover the ratio and the finished formulation, adding further independently claimable layers.

How AI-powered landscape and FTO analysis helps

A modular, multi-owner, actively litigated landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant antibody, linker, payload, and conjugation claims regardless of terminology, attribution that resolves the many owners to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and litigation developments. Because ADC advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the landscape is extending.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as antibody-drug conjugates across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, antibody, linker, payload, and conjugation, and normalizes owners to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where next-generation linkers and payloads emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is freedom-to-operate hard for antibody-drug conjugates? Freedom-to-operate is hard for antibody-drug conjugates because an ADC is a modular product whose antibody, linker, payload, conjugation chemistry, and drug-to-antibody ratio are each independently patentable and often held by different owners. Clearing one layer does not clear the others. FTO must therefore be assessed layer by layer across multiple patent families.

What are the main claim types in the ADC landscape? The main claim types are antibody claims, linker claims, payload claims, conjugation and site-specific claims, and drug-to-antibody-ratio and formulation claims. Each covers a distinct layer of the ADC and can independently create infringement risk. The linker and conjugation layers are especially heavily patented and litigated.

What was the Seagen v. Daiichi Sankyo dispute about? The Seagen v. Daiichi Sankyo dispute concerned linker technology used in a blockbuster HER2-targeted ADC. A jury had found for Seagen and awarded damages, but on December 2, 2025 the US Court of Appeals for the Federal Circuit reversed, holding Seagen's key linker patent invalid for lack of written description and enablement and vacating the award. It illustrates how the linker layer drives ADC freedom-to-operate risk and how even a trial win can be undone on validity grounds.

How fast is ADC patenting growing? ADC patenting has grown rapidly, with ADC-specific patent families more than doubling between 2018 and 2024 in the Cypris corpus. Growth has been driven by potent topoisomerase-1 payloads, new linker and site-specific conjugation technologies, and expansion from hematologic cancers into solid tumors. Because applications publish about eighteen months after filing, recent activity is under-represented.

What is a payload estate and why does it matter for FTO? A payload estate is the set of patents an organization holds around a specific cytotoxic payload class and its use in ADCs. It matters for FTO because a strong payload estate, such as the one around the DXd payload, can create infringement exposure for follow-on and biosimilar ADCs in markets where it is in force. Developers must assess payload IP as a distinct layer.

Why does ADC analysis need scientific literature? ADC analysis needs scientific literature because linker, payload, and conjugation advances appear in research before they are patented, so the literature gives the earliest signal of where the landscape is extending. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams need ADC patent landscape and FTO analysis? ADC patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at pharmaceutical and biotech companies developing ADCs, payloads, linkers, and conjugation platforms, as well as investors assessing ADC assets. The modular, litigated landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

How current does an ADC landscape need to be? An ADC landscape needs to be continuously current, because litigation is active, next-generation linker and payload filings publish constantly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track the landscape and flag new filings and developments as they publish.

‍